Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell mobilization in normal donors

A Tabilio1, F Falzetti, C Giannoni

  • 1Department of Clinical Medicine, Pathology, and Pharmacology, Haematology, University of Perugia, Italy.

Journal of Hematotherapy
|June 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toxicological risk profiles in suicide: The forensic value of hair-based substance detection.

Legal medicine (Tokyo, Japan)·2026
Same author

HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia.

Bone marrow transplantation·2023
Same author

Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases.

Mycoses·2018
Same author

Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria.

Annals of hematology·2018
Same author

Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2017
Same author

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same journal

Comparative evaluation of procedures with a Baxter CS-3000 cell separator for collecting peripheral blood cells from children.

Journal of hematotherapy·1999
Same journal

Graft engineering of G-CSF-mobilized allogeneic leukapheresis products by counterflow centrifugal elutriation after CD34 column adsorption.

Journal of hematotherapy·1999
Same journal

Serum granulocyte colony-stimulating factor kinetics in children receiving intense chemotherapy with or without stem cell support.

Journal of hematotherapy·1999
Same journal

Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92.

Journal of hematotherapy·1999
Same journal

The differentiating effect of retinoic acid and vincristine on acute myeloid leukemia.

Journal of hematotherapy·1999
Same journal

Comparison of T-cell-depleted BMT and PBPCT with respect to chimerism, graft rejection, and leukemic relapse.

Journal of hematotherapy·1999
See all related articles

Recombinant human granulocyte-colony stimulating factor (rhG-CSF) effectively mobilizes hematopoietic progenitor cells for peripheral blood stem cell (PBSC) collection. Bone marrow harvesting prior to rhG-CSF treatment does not negatively impact PBSC mobilization in normal donors.

Area of Science:

  • Hematology
  • Transplantation Immunology
  • Cellular Therapy

Background:

  • Bone marrow transplantation (BMT) relies on the collection of hematopoietic stem and progenitor cells.
  • Recombinant human granulocyte-colony stimulating factor (rhG-CSF) is used to mobilize these cells into peripheral blood.
  • The optimal timing and impact of prior bone marrow harvesting on subsequent PBSC mobilization are important considerations.

Purpose of the Study:

  • To evaluate the efficacy of a specific rhG-CSF administration protocol for mobilizing hematopoietic progenitor cells.
  • To assess the impact of prior bone marrow harvesting on the quantity of mobilized peripheral blood stem cells (PBSCs).
  • To determine the optimal timing for leukapheresis during rhG-CSF treatment.

Main Methods:

Related Experiment Videos

  • Studied 39 normal donors undergoing rhG-CSF treatment for BMT.
  • Administered rhG-CSF (12 µg/kg/day) via continuous subcutaneous infusion for 4-7 days.
  • Harvested bone marrow 1-7 days before rhG-CSF initiation; performed leukapheresis on days 4-7.

    • Main Results:

    • Peak CD34+ cell and CFU-GM levels occurred on days 5-6 of rhG-CSF treatment.
    • Median peak CD34+ cell levels were 1.65% and CFU-GM levels were 142/10^5 plated cells.
    • Maximal collection of CD34+ cells and CFU-GM per liter processed occurred during the second and third leukaphereses.

    Conclusions:

    • The rhG-CSF mobilization protocol effectively increases peripheral blood hematopoietic progenitor cells.
    • Bone marrow harvesting prior to rhG-CSF administration does not compromise stem cell mobilization.
    • The second and third leukapheresis sessions yield the highest numbers of mobilized stem cells.